Ariceum is a clinical-stage radiopharmaceutical company currently focused on the precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum’s lead targeted systemic radiopharmaceutical drug, Satoreotide, is an antagonist of the somatostatin type 2 receptor, which is overexpressed in neuroendocrine tumours and other aggressive cancers, with few treatment options and poor prognosis.